|View printer-friendly version|
Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
During the investor event, Portola’s senior management team will provide updates on clinical, regulatory and manufacturing milestones for its three wholly-owned product candidates, AndexXa™ (andexanet alfa), betrixaban and cerdulatinib.
To access the live investor webcast on
About Portola Pharmaceuticals, Inc.
Ana Kapor Portola Pharmaceuticalsir@portola.com Media Contact: Julie Normart W2O Groupjnormart@w2ogroup.com